Pfizer Inc. is paying $1.25 billion up front and up to $4.8 billion in milestone payments to gain global, ex-China rights to SSGJ-707, a PD-1/VEGF bispecific antibody from 3Sbio Inc. that recently won ...

BMO Capital analyst Evan Seigerman maintained a Buy rating on Pfizer Inc. (NYSE:PFE) and kept the price target the same at ...

The U.S. FDA will offer feedback and other assistance to states that want to allow importation of prescription drugs from ...